The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Nielsen Kirk G. | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Nielsen Kirk G. | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Jain Mudit K. | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Jain Mudit K. | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Slattery Joseph P | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Slattery Joseph P | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Hill, Mitch C. | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Hill, Mitch C. | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Ballinger Kevin J. | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Ballinger Kevin J. | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Shadan Martha | Director | Grant(A) | 9K | — | $0 |
| Jun 1, 2026 | Shadan Martha | Director | Grant(A) | 11K | — | $0 |
| Jun 1, 2026 | Dale Michael D | Director | Grant(A) | 29K | — | $0 |
| Jun 1, 2026 | Dale Michael D | Director | Grant(A) | 36K | — | $0 |
| Mar 2, 2026 | Morrison Gregory | CHIEF HUMAN RESOURCES OFFICER | Grant(A) | 34K | — | $0 |
| Mar 2, 2026 | Morrison Gregory | CHIEF HUMAN RESOURCES OFFICER | Grant(A) | 155K | — | $0 |
| Mar 2, 2026 | Hykes Kevin | PRES & CEO, Director | Sell(S) | 8K | $7.90 | $61K |
| Mar 2, 2026 | John Robert Allen | Chief Revenue Officer | Sell(S) | 4K | $7.90 | $31K |
| Mar 2, 2026 | Oasheim Jared | CHIEF FINANCIAL OFFICER | Sell(S) | 2K | $7.90 | $14K |
| Mar 2, 2026 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Sell(S) | 1K | $7.90 | $10K |
| Mar 2, 2026 | Adamson Philip B. | Chief Medical Officer | Sell(S) | 1K | $7.90 | $10K |
| Feb 27, 2026 | Hykes Kevin | PRES & CEO, Director | Grant(A) | 159K | — | $0 |
| Feb 27, 2026 | Hykes Kevin | PRES & CEO, Director | Grant(A) | 238K | — | $0 |
| Feb 27, 2026 | John Robert Allen | Chief Revenue Officer | Grant(A) | 35K | — | $0 |
| Feb 27, 2026 | John Robert Allen | Chief Revenue Officer | Grant(A) | 52K | — | $0 |
| Feb 27, 2026 | Binkowski Brent | CHIEF OPERATING OFFICER | Grant(A) | 15K | — | $0 |
| Feb 27, 2026 | Binkowski Brent | CHIEF OPERATING OFFICER | Grant(A) | 23K | — | $0 |
| Feb 27, 2026 | Oasheim Jared | CHIEF FINANCIAL OFFICER | Grant(A) | 61K | — | $0 |
| Feb 27, 2026 | Oasheim Jared | CHIEF FINANCIAL OFFICER | Grant(A) | 91K | — | $0 |
| Feb 27, 2026 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Grant(A) | 45K | — | $0 |
| Feb 27, 2026 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Grant(A) | 67K | — | $0 |
| Feb 27, 2026 | Adamson Philip B. | Chief Medical Officer | Grant(A) | 41K | — | $0 |
| Feb 27, 2026 | Adamson Philip B. | Chief Medical Officer | Grant(A) | 62K | — | $0 |
| Feb 20, 2026 | Jain Mudit K. | Director | Buy(P) | 47K | $6.36 | $298K |
| Feb 18, 2026 | Jain Mudit K. | Director | Buy(P) | 600 | $4.64 | $3K |
| Nov 26, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 6K | $10.03 | $64K |
| Nov 26, 2025 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Sell(S) | 6K | $10.03 | $64K |
| Nov 25, 2025 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Sell(S) | 16K | $10.03 | $160K |
| Nov 24, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 2K | $10.06 | $22K |
| Nov 21, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 500 | $10.00 | $5K |
| Nov 12, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 1K | $10.00 | $10K |
| Nov 7, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 200 | $10.00 | $2K |
| Nov 6, 2025 | Johnson & Johnson | 10% Owner | Sell(S) | 52K | $10.21 | $534K |
| Aug 11, 2025 | Binkowski Brent | CHIEF OPERATING OFFICER | Grant(A) | 17K | — | $0 |
| Aug 11, 2025 | Binkowski Brent | CHIEF OPERATING OFFICER | Grant(A) | 75K | — | $0 |
| Jun 3, 2025 | Shadan Martha | Director | Grant(A) | 20K | — | $0 |
| Jun 3, 2025 | Ballinger Kevin J. | Director | Grant(A) | 20K | — | $0 |
| Jun 3, 2025 | Hill, Mitch C. | Director | Grant(A) | 20K | — | $0 |
| Jun 3, 2025 | Slattery Joseph P | Director | Grant(A) | 20K | — | $0 |
| Jun 3, 2025 | Jain Mudit K. | Director | Grant(A) | 20K | — | $0 |
| Jun 3, 2025 | Nielsen Kirk G. | Director | Grant(A) | 20K | — | $0 |
| May 15, 2025 | Nielsen Kirk G. | Director | Buy(P) | 11K | $5.45 | $60K |
| May 14, 2025 | Nielsen Kirk G. | Director | Buy(P) | 61K | $5.23 | $320K |
| May 13, 2025 | Nielsen Kirk G. | Director | Buy(P) | 101K | $5.29 | $536K |
| May 13, 2025 | Jain Mudit K. | Director | Buy(P) | 150 | $5.26 | $789 |
| May 12, 2025 | Nielsen Kirk G. | Director | Buy(P) | 25K | $4.79 | $121K |
| May 12, 2025 | Hykes Kevin | PRES & CEO, Director | Buy(P) | 5K | $4.84 | $24K |
| May 12, 2025 | Jain Mudit K. | Director | Buy(P) | 2K | $4.66 | $7K |
| Feb 28, 2025 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Grant(A) | 16K | — | $0 |
| Feb 28, 2025 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Grant(A) | 24K | — | $0 |
| Feb 28, 2025 | Adamson Philip B. | Chief Medical Officer | Grant(A) | 20K | — | $0 |
| Feb 28, 2025 | Adamson Philip B. | Chief Medical Officer | Grant(A) | 30K | — | $0 |
| Feb 28, 2025 | Oasheim Jared | CHIEF FINANCIAL OFFICER | Grant(A) | 22K | — | $0 |
| Feb 28, 2025 | Oasheim Jared | CHIEF FINANCIAL OFFICER | Grant(A) | 33K | — | $0 |
| Feb 28, 2025 | John Robert Allen | Chief Revenue Officer | Grant(A) | 55K | — | $0 |
| Feb 28, 2025 | John Robert Allen | Chief Revenue Officer | Grant(A) | 38K | — | $0 |
| Feb 28, 2025 | Hykes Kevin | PRES & CEO, Director | Grant(A) | 98K | — | $0 |
| Feb 28, 2025 | Hykes Kevin | PRES & CEO, Director | Grant(A) | 148K | — | $0 |
| Nov 21, 2024 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Gift(G) | 1K | — | $0 |
| Nov 19, 2024 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Sell(S) | 1K | $13.58 | $19K |
| Nov 19, 2024 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Option exercise(M) | 3K | $5.14 | $13K |
| Nov 19, 2024 | Verrastro Paul | CHIEF MKTG & STRAT OFFICER | Option exercise(M) | 3K | — | $0 |
| Sep 3, 2024 | Hill, Mitch C. | Director | Grant(A) | 36K | — | $0 |
| Sep 3, 2024 | Ballinger Kevin J. | Director | Grant(A) | 36K | — | $0 |
| Aug 15, 2024 | Slattery Joseph P | Director | Buy(P) | 3K | $8.10 | $24K |
| Aug 8, 2024 | Slattery Joseph P | Director | Buy(P) | 3K | $8.24 | $25K |
| Aug 6, 2024 | Slattery Joseph P | Director | Buy(P) | 3K | $9.09 | $23K |
| Aug 5, 2024 | Hykes Kevin | PRES & CEO, Director | Buy(P) | 30K | $8.36 | $251K |
| Jul 31, 2024 | Hykes Kevin | PRES & CEO, Director | Grant(A) | 180K | — | $0 |
| Jun 27, 2024 | John Robert Allen | Chief Revenue Officer | Grant(A) | 122K | — | $0 |
| Jun 4, 2024 | Behbahani Ali | Director | Grant(A) | 27K | — | $0 |
| Jun 4, 2024 | Shadan Martha | Director | Grant(A) | 27K | — | $0 |
| Jun 4, 2024 | Jain Mudit K. | Director | Grant(A) | 27K | — | $0 |
| Jun 4, 2024 | Slattery Joseph P | Director | Grant(A) | 27K | — | $0 |
| Jun 4, 2024 | Nielsen Kirk G. | Director | Grant(A) | 27K | — | $0 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 151 | $0.24 | $36 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 404 | $0.24 | $97 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 379 | $0.24 | $91 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 379 | — | $0 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 151 | — | $0 |
| Mar 25, 2024 | Palmer Craig E. | SVP, U.S. SALES | Option exercise(M) | 404 | — | $0 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 142 | $1.19 | $169 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 252 | $3.96 | $998 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 442 | $1.19 | $526 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 300 | $0.24 | $72 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 584 | $0.24 | $140 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 489 | $0.24 | $117 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 758 | $0.24 | $182 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 85 | $0.24 | $20 |
| Feb 29, 2024 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Option exercise(M) | 23 | $0.24 | $6 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-01-04 → 2026-07-21. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).